Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 76, Issue 11, Pages 1862-1869Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2017-211149
Keywords
-
Categories
Funding
- Dutch Arthritis Foundation [BP12-1-161]
- National Institute for Health Research (NIHR) Collaborations for Leadership inApplied Research and Care West Midlands
- Knowledge Mobilisation Research Fellowship from the NIHR [KMRF-2014-03-002]
- National Institute for Health Research (NIHR)
- Arthritis Research UK
- Sanofi Aventis
- Abbvie
- Fidia
- Samumed
- Pfizer
- Flexion Therapeutics
- Plexxikon Inc
- Regeneron
- Orthogen
- McNeil Consumer HC
- Galapagos NV
- FlexionTherapeutics
- Johnson Johnson
- Ossur
- National Institute for Health Research [RP-PG-0407-10386, KMRF-2014-03-002] Funding Source: researchfish
- ReumaFonds [COI-1, LLP-11] Funding Source: researchfish
Ask authors/readers for more resources
Objective T o evaluate the effectiveness of oral glucosamine in subgroups of people with hip or knee osteoarthritis (OA) based on baseline pain severity, body mass index (BMI), sex, structural abnormalities and presence of inflammation using individual patient data. Methods After a systematic search of the literature and clinical trial registries, all randomised controlled trials (RCTs) evaluating the effect of any oral glucosamine substance in patients with clinically or radiographically defined hip or knee OA were contacted. As a minimum, pain, age, sex and BMI at baseline and pain as an outcome measure needed to be assessed. Results Of 21 eligible studies, six (n=1663) shared their trial data with the OA Trial Bank. Five trials (all independent of industry, n=1625) compared glucosamine with placebo, representing 55% of the total number of participants in all published placebo-controlled RCTs. Glucosamine was no better than placebo for pain or function at short (3 months) and long-term (24 months) follow-up. Glucosamine was also no better than placebo among the predefined subgroups. Stratification for knee OA and type of glucosamine did not alter these results. Conclusions Although proposed and debated for several years, open trial data are not widely made available for studies of glucosamine for OA, especially those sponsored by industry. Currently, there is no good evidence to support the use of glucosamine for hip or knee OA and an absence of evidence to support specific consideration of glucosamine for any clinically relevant OA subgroup according to baseline pain severity, BMI, sex, structural abnormalities or presence of inflammation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available